Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
The company will respond to the US FDA within the stipulated timelines
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Subscribe To Our Newsletter & Stay Updated
